Gyre Therapeutics (GYRE) Registration filing summary

Company overview and business model

• Commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases, with operations in the U.S. and China through subsidiaries.

• Recently completed an all-stock merger with Cullgen, integrating targeted protein degrader technology and expanding therapeutic focus to include cancers and pain.

• Operations in China expose the company to unique legal and regulatory risks, including government oversight and restrictions on capital movement.

Financial performance and metrics

• As of May 31, 2026, 111,488,849 shares of common stock were outstanding.

• No periodic cash dividends are anticipated for the foreseeable future; past special dividends were paid in 2022 and 2023.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be at $4,915 per share.

• Company will bear registration and listing costs, while selling stockholders cover their own transaction expenses.